Digital Technology Helps Improve Lung Cancer Pathology
Pathologists are charged with the task of studying biopsy samples from patients to diagnose disease and to aid in disease management. While lung cancer pathology is becoming
Pathologists are charged with the task of studying biopsy samples from patients to diagnose disease and to aid in disease management. While lung cancer pathology is becoming
Some lung cancer patients respond well to treatment with checkpoint inhibitor immunotherapy, which allows the body’s immune system to identify and attack cancer cells. However
Dr. Donington is Professor and Chief of the Section of General Thoracic Surgery at University of Chicago Medicine. Her clinical and interests focus on the early diagnosis and
As the treatment options for lung cancer patients are evolving to include biomarker-based precision medicine, the design of clinical trials is changing too. The majority of
Kristin Higgins, MD is an Associate Professor within the Emory School of Medicine and serves as the Medical Director of Radiation Oncolo-gy at the main campus location. She
In the past 10 years, lung cancer has seen significant progress in patient outcomes that would not have been possible without translational research. Translational research fills
Approximately 5% of non-small cell lung cancer patients have tumors resulting from the fusion of the ALK gene with another gene (usually EML4). While there are a number of tyrosine
Erin Charla Peterson, LCSW, is Senior Social Work Counselor at The University of Texas MD Anderson Cancer Center. She is a Licensed Clinical Social Worker who provides counseling
Brett Bade, MD, is a pulmonologist at Yale University and the West Haven Veterans Affairs Medical Center. He has board certifications in Internal Medicine, Pulmonology, and
In recent years, immunotherapy, a treatment that enhances the body’s own immune cancer-fighting response, has been shown to be a very promising treatment option. Immunotherapy has
Since the discovery of the first epidermal growth factor receptor (EGFR) mutation in lung cancer in 2004, targeted therapies and immunotherapies have become a major component of